BIAF

BioAffinity Technologies Inc

2.42

Nov 11 • 3:59 PM ET +0.03 (1.46%)

2.50

Aftermarket • 7:30 PM ET +0.07 (2.90%)

Healthcare Diagnostics & Research USA Nano NASD

Nov 11, 8:07 AMbioAffinity Technologies' CyPath Lung test hits record 235 tests in October 2026, up 29% year over year

Peers: BDSX VCYT ADVB MDXH PRPO GH IMDX LUCD XGN QTRX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	4.41M
Enterprise Value	3.36M
Income	-15.41M
Sales	5.53M
Book/sh	3.36
Cash/sh	1.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	57
IPO	Sep 01, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	0.80
P/B	0.72
P/C	1.73
P/FCF	-
EV/EBITDA	-
EV/Sales	0.61
Quick Ratio	1.47
Current Ratio	1.51
Debt/Eq	0.38
LT Debt/Eq	0.28
Option/Short	No / Yes

EPS (ttm)	-38.13
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	45.79% 21.77%
Sales past 3/5Y	986.60% -
EPS Y/Y TTM	87.82%
Sales Y/Y TTM	-18.47%
EPS Q/Q	91.71%
Sales Q/Q	-25.99%
Earnings	Nov 06 AMC
EPS/Sales Surpr.	- -

Insider Own	0.82%
Insider Trans	0.00%
Inst Own	3.72%
Inst Trans	6.08%
ROA	-161.37%
ROE	-240.48%
ROIC	-306.97%
Gross Margin	20.41%
Oper. Margin	-246.14%
Profit Margin	-278.93%
SMA20	-20.19%
SMA50	-57.61%
SMA200	-86.93%
Trades

Shs Outstand	1.82M
Shs Float	1.81M
Short Float	2.95%
Short Ratio	0.01
Short Interest	0.05M
52W High	80.70 -97.00%
52W Low	2.25 7.78%
Volatility	15.05% 11.66%
ATR (14)	0.56
RSI (14)	34.04
Beta	-0.99
Rel Volume	0.02
Avg Volume	3.67M
Volume	76,436

Perf Week	-17.24%
Perf Month	-33.10%
Perf Quarter	-57.79%
Perf Half Y	-91.45%
Perf YTD	-86.30%
Perf Year	-92.52%
Perf 3Y	-99.63%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	2700.00
Prev Close	2.39
Price	2.42
Change %	1.46%

Nov-11-26 10:02AM	bioAffinity Technologies posts record monthly volume for CyPath Lung test (Proactive)
08:00AM	bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath Lung Test (Business Wire)
Nov-06-26 05:40PM	bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath Lung Commercialization (Business Wire) -16.76%
Oct-15-26 08:00AM	bioAffinity Technologies to Present New Perspectives on CyPath Lungs Use for Cancer Risk Assessment at CHEST 2026 (Business Wire) +11.24%
Oct-09-26 12:30PM	WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -16.22%
11:37AM	Loading…
11:37AM	bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (Business Wire)
Oct-08-26 01:30PM	WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -8.44%
12:07PM	bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (Business Wire)
10:34AM	bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test (InvestorsHub)
08:00AM	bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath Lung and AI-Built Algorithm (Business Wire)
Sep-30-26 08:00AM	bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL (Business Wire)
Sep-28-26 05:17AM	bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection (InvestorsHub) -6.56%
Sep-22-26 10:41AM	bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans' Research Conference (InvestorsHub) +11.10%
Sep-17-26 10:21AM	bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic (InvestorsHub) +63.55%
08:00AM	bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath Lung Noninvasive Lung Cancer Diagnostic (Business Wire)
08:21AM	Loading…
Sep-03-26 08:21AM	bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update (InvestorsHub) +31.08%
Sep-01-26 11:03AM	bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance (InvestorsHub) +44.52%
Aug-20-26 08:00AM	bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 (Business Wire)
Aug-18-26 10:43AM	bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung (InvestorsHub) +20.74%
08:00AM	bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath Lung (Business Wire)
Aug-14-26 11:45AM	WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
11:07AM	bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules (Business Wire)
Aug-13-26 10:00AM	WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -18.98%
09:07AM	bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules (Business Wire)
Aug-07-26 08:00AM	bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath Lung (Business Wire)
Jul-27-26 08:08AM	bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath Lung (Business Wire)
Jul-22-26 08:08AM	bioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinitys Diagnostics for Asthma and COPD (Business Wire)
Jun-22-26 08:00AM	bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells (Business Wire)
Jun-18-26 02:54PM	WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering (PR Newswire)
01:16PM	bioAffinity Technologies Announces Closing of $3.2 Million Offering (Business Wire)
10:41AM	Loading…
Jun-17-26 10:41AM	WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering (PR Newswire) -11.96%
09:25AM	bioAffinity Technologies Announces Pricing of $3.2 Million Offering (Business Wire)
Jun-16-26 08:06AM	bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans (Business Wire) -31.04%
May-27-26 08:00AM	bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath Lung Technology (Business Wire)
May-12-26 09:15AM	bioAffinity Technologies Reports Record Monthly CyPath Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 (Business Wire)
May-08-26 08:30AM	bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath Lung (Business Wire)
Apr-28-26 09:16AM	bioAffinity Technologies Launches New Study To Expand Use of CyPath Lung Technology for Asthma and COPD Diagnosis and Treatment (Business Wire) +20.36%
Apr-14-26 08:00AM	New Case Study: bioAffinity Technologies CyPath Lung Diagnostic Supports Physicians Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy (Business Wire) -11.64%
Apr-07-26 08:00AM	bioAffinity Technologies CyPath Lung to Be Featured at Cleveland Clinic Annual Advances in Early Lung Cancer Detection Symposium April 16 (Business Wire)
Apr-01-26 08:00AM	bioAffinity Technologies CyPath Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 (Business Wire)
Mar-25-26 08:00AM	bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath Lung into Pulmonary Practice (Business Wire)
Mar-17-26 07:45AM	New Case Study: bioAffinity Technologies CyPath Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures (Business Wire) +43.46%
Mar-13-26 08:00AM	bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath Lung (Business Wire) +98.13%
Mar-10-26 07:47AM	bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath Lung Cancer Diagnostic (Business Wire) +12.26%
Mar-05-26 11:51AM	BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? (Zacks)
Mar-03-26 08:30AM	bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients (Business Wire) -10.31%
Feb-25-26 08:30AM	bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath Lung Noninvasive Early Detection Lung Cancer Test (Business Wire)
Feb-19-26 11:00AM	New Case Study Highlights Ability of bioAffinity Technologies CyPath Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer (Business Wire)
Feb-17-26 08:00AM	Clinical Utility of bioAffinity Technologies CyPath Lung Test Demonstrated in Real-World Case Study (Business Wire)
Feb-09-26 08:00AM	bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board (Business Wire) +5.73%
Jan-07-26 08:00AM	bioAffinity Technologies Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation (Business Wire)
Dec-03-25 08:00AM	bioAffinity Technologies Noninvasive CyPath Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable (Business Wire) +9.79%
Nov-19-25 11:33AM	BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss (Zacks)
Nov-14-25 08:00AM	bioAffinity Technologies Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-28-25 08:00AM	bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases (Business Wire)
Oct-16-25 08:00AM	bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer (Business Wire) +25.83%
Oct-15-25 08:00AM	bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements (Business Wire) -5.90%
Oct-09-25 02:00PM	WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (PR Newswire)
01:00PM	bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (Business Wire)
Oct-08-25 04:15PM	WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (PR Newswire) +24.49%
03:45PM	bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (Business Wire)
Oct-07-25 08:00AM	bioAffinity Technologies Reports Record Growth in CyPath Lung Test Volume for Third Quarter 2025 (Business Wire)
Sep-30-25 12:44PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m (PR Newswire) -8.92%
12:15PM	bioAffinity Technologies Announces Closing of $4.8 Million Public Offering (Business Wire)
Sep-29-25 05:59PM	WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m (PR Newswire) -38.56%
03:51PM	bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering (Business Wire)
Sep-26-25 08:00AM	bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath Lung (Business Wire) +55.13%
Sep-17-25 08:15AM	bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 (Business Wire) -30.04%
Sep-09-25 08:00AM	Case Study: CyPath Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules (Business Wire)
Sep-03-25 08:00AM	U.S. Medicine Magazine Spotlights CyPath Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA (Business Wire)
Aug-21-25 02:58PM	BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth (Zacks)
Aug-18-25 08:00AM	bioAffinity Technologies Appoints New Members to Board of Directors (Business Wire) +5.11%
Aug-14-25 04:20PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (PR Newswire) -8.86% -8.66%
04:15PM	bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (Business Wire)
08:00AM	bioAffinity Technologies Reports Second Quarter 2025 Results (Business Wire)
Aug-13-25 10:15AM	WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (PR Newswire)
09:25AM	bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (Business Wire)
08:00AM	bioAffinity Technologies Reports Accelerating Growth in CyPath Lung Test Sales (Business Wire)
Jul-29-25 08:00AM	Case Study: CyPath Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results (Business Wire)
Jul-23-25 08:00AM	Case Study: CyPath Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools (Business Wire)
Jul-22-25 09:00AM	Canada Awards New Patent to bioAffinity Technologies for CyPath Lung, Companys Noninvasive Lung Cancer Diagnostic (Business Wire) -6.03%
Jul-15-25 09:00AM	bioAffinity Technologies Announces Notification of China Patent Award for Companys Noninvasive Lung Cancer Diagnostic (Business Wire)
Jul-09-25 09:00AM	Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging (Business Wire)
Jul-01-25 09:33AM	The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies (Zacks) -8.25%
Jun-30-25 04:41PM	Top Research Reports for Meta Platforms, ServiceNow & Booking (Zacks)
Jun-26-25 09:00AM	bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference (Business Wire) +46.90%
Jun-24-25 09:00AM	bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy (Business Wire) +7.73%
Jun-11-25 09:00AM	bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas Leadership Board (Business Wire)
Jun-03-25 09:00AM	bioAffinity Technologies Works With Cardinal Health OptiFreight® Logistics to Help Meet Demand for CyPath® Lung (Business Wire) +7.58%
May-29-25 02:34PM	BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors (Insider Monkey) -15.83%
May-28-25 09:00AM	bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics (Business Wire) +46.84%
May-20-25 12:15PM	BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline (Zacks) +29.79%
09:00AM	bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer (Business Wire)
May-15-25 08:30AM	bioAffinity Technologies Reports First Quarter 2025 Results (Business Wire) -8.62%
May-08-25 09:00AM	Independent White Paper Highlights Real-World Impact of bioAffinity Technologies CyPath® Lung in Diagnosing Early-Stage Lung Cancer (Business Wire) -5.31%
May-07-25 01:15PM	WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering (PR Newswire)
01:00PM	bioAffinity Technologies Announces Closing of $3.25 Million Offering (Business Wire)
10:40AM	BioAffinity Technologies announces pricing of $3.25M offering (TipRanks)
May-06-25 10:30AM	WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering (PR Newswire) -44.50%
09:25AM	bioAffinity Technologies Announces Pricing of $3.25 Million Offering (Business Wire)

Show Previous News

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Founder & Executive Chairman of the BoardMr. Steven Girgenti

FounderMs. Maria Zannes J.D.

M.B.A.Mr. James Michael Edwards CPA

Chief Operating OfficerMr. Xavier T. Reveles M.S.

Chief Science OfficerDr. William Bauta Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

BIAF

BioAffinity Technologies Inc

Upgrade your Finviz experience

All the Features.
Half the Price.